Document is current

Article History

Received: 26 July 2024

Accepted: 6 December 2024

First Online: 19 December 2024

Declarations

:

: The study was conducted in accordance with the Declaration of Helsinki and its amendments, and it was approved by the Osaka Medical College and the Faculties of Medicine Ethics Committee (approval no. 1529) and by the individual participating centres, including Kyoto University (approval no. R1540) and Osaka Metropolitan University (approval no. 2023-027). The Ethics Committee of Kyoto University waived the requirement for informed consent because of the anonymous nature of the data. Written informed consent was obtained from each patient at the other institutions.

: Not applicable.

: SM has received research grant from Japan Intractable Diseases Research Foundation and Promotion and Mutual Aid Corporation for Private Schools of Japan. TK has received payments for lectures from Abbvie, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Pfizer, and Boehringer Ingelheim. RW receives research grant from AbbVie and speaker’s fee from Asahi Kasei, Chugai, Eli Lilly, GSK, and UCB Japan. RH received research grants from GSK, and speaker fee from Abbvie, Asahi Kasei, Brystol-Meyers Squibb, Eisai, Eli Lilly, GSK, Kissei, and Pfizer. MH received research grants and/or speaker fee from Abbvie, Asahi Kasei, Astellas, Brystol Meyers, Chugai, Eisai, Daiichi Sankyo, Eli Lilly, Novartis Pharma, Tanabe Mitsubishi. TT received research grants and/or speaker fee from Abbvie, Asahi Kasei, Astellas, Brystol-Meyers Squibb, Chugai, Eisai, Eli Lilly, Janssen pharma, Nihon Shinyaku, Mitsubishi-Tanabe, Takeda, and Pfizer. Other authors (AO, DN, YM, MS, TT, AM, KK, TY, WY) do not have any conflict of interest.